WVE Stock Soars on Upbeat Efficacy Data From Muscle Disease Study [Yahoo! Finance]
Wave Life Sciences Ltd. - Ordinary Shares (WVE)
Last wave life sciences ltd. - ordinary shares earnings: 3/2 06:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.wavelifesciences.com/news-releases?page=1%2c0%2c0%2c0
Company Research
Source: Yahoo! Finance
Shares of Wave Life Sciences WVE surged 53.4% on Tuesday after the company announced positive interim data from a mid-stage study evaluating its investigational candidate, WVE-N531, to treat boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping. WVE-N531, an exon skipping oligonucleotide, is currently being developed as a disease-modifying treatment for DMD indication in boys. The candidate enjoys the FDA's Orphan Drug and Rare Pediatric Disease designations in the United States for the same indication. The data readout is from the planned interim analysis of the phase II FORWARD-53 study after 24 weeks, where the DMD patients received a 10 mg/kg dose of WVE-N531 every two weeks. Per Wave Life Sciences, treatment with the candidate demonstrated substantial dystrophin expression and was generally safe and overall well tolerated. WVE expects to share 48-week data from the complete FORWARD-53 study of WVE-N531 for DMD in the first quarter of 2025 and rec
Show less
Read more
Impact Snapshot
Event Time:
WVE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WVE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WVE alerts
High impacting Wave Life Sciences Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
WVE
News
- Wave Life Sciences Ltd. (NASDAQ: WVE) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $13.00 price target on the stock.MarketBeat
- Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants [Yahoo! Finance]Yahoo! Finance
- Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsGlobeNewswire
- Wave Life Sciences Ltd. (NASDAQ: WVE) had its price target raised by analysts at HC Wainwright from $15.00 to $22.00. They now have a "buy" rating on the stock.MarketBeat
- Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded WarrantsGlobeNewswire
WVE
Earnings
- 8/8/24 - Miss
WVE
Sec Filings
- 9/27/24 - Form 4
- 9/27/24 - Form 424B5
- 9/26/24 - Form 8-K
- WVE's page on the SEC website